People

Meera Mani is a physician and Town Hall Ventures general partner listed in Qualified Health’s investor and adviser roster. She previously worked in McKinsey’s healthcare practice, including leadership on Medicaid. Her experience covers insurers, health systems, public agencies and healthcare investors, with a focus on care access and underserved populations. Existing Town Hall affiliations are preserved; no personal cash ticket is inferred. CHCF Innovation Fund adviser, physician and neuroscientist. Her own CHCF biography describes healthcare-AI, youth-mental-health and dementia investment experience, prior McKinsey healthcare leadership and Town Hall Ventures affiliation.

David Whelan is publicly listed by Thyme Care as Board Member. The directory describes their outside affiliation as Founder & General Partner, Town Hall Ventures; that title is context, not an executive position at Thyme Care.

Andy Slavitt is the published president of Qualified Health’s advisory board. He co-founded Town Hall Ventures and previously served as head of the Centers for Medicare and Medicaid Services and as a White House adviser on the COVID response. His public and private-sector experience centers on healthcare access, policy and delivery. The advisory role is distinguished from the company’s statutory board of directors.

Executive assistant and operations support professional at Bison Ventures with experience in finance, startups and arts institutions. Studied anthropology at the University of Michigan and history of art and curating at UCL.

Bison Ventures principal with infrastructure and technology investment experience at G2 Venture Partners, Morgan Stanley Infrastructure Partners and Barclays. Holds degrees in operations research and financial engineering from Princeton, systems engineering from the University of Pennsylvania, and an MBA from Wharton.

Bison Ventures principal with biomedical engineering and frontier technology investment experience. Previously spent five years at Braemar Energy Ventures. Interests include neuromorphic computing, regenerative medicine, spatial computing and environmental technologies. Educated at Brown, USC and Harvard Business School.

Bison Ventures partner focused on technology-enabled biology and AI in the physical world. A biomedical engineer previously investing at Innovation Endeavors and leading TuneIn's global subscription business as senior vice president and general manager. Holds a biomedical engineering degree from Georgia Tech.

Bison Ventures founding partner and engineer with frontier technology investment experience at Cascade Asset Management and Altira Group. Previously worked in semiconductor manufacturing at Intel and solar photovoltaic technology development. Holds a Cornell materials science and engineering degree and a Kellogg MBA.

Neuroscientist and venture investor with a PhD from Columbia University and an MBA from Harvard Business School. Founded Arkitekt Ventures to invest in healthcare and life sciences innovation.

Sooah Cho is a SignalFire partner focusing on health and life-sciences technology, with previous product and investment work at CVS Health, Devoted Health and Underscore VC. She led SignalFire’s January2025 Qualified Health investment and stated that she joined its board. The July2026 SEC filing independently identifies her as a statutory director. Existing SignalFire identity and affiliations remain preserved. Sooah Cho is named as a Doro Mind director in its March2026 FormD. She is a SignalFire partner focused on early-stage health and life-sciences technology; the board role does not imply a personal cash investment or full-time clinical employment.

Jerry Yang is the Founding Partner of AME Cloud Ventures, supporting entrepreneurs working on data, cloud computing, hardware and deep technology. He co-founded Yahoo in 1995 and served in executive and board capacities through 2012, helping establish relationships with Yahoo Japan and Alibaba. SignalFire’s own biography independently identifies him as AME’s founding partner, confirming reuse of this existing advisor profile. AME’s older outside board wording is not treated as proof of current 2026 appointments. This Yahoo founder is distinct from the retained HCVC investor with the same name.

Juvena Therapeutics senior vice president of drug development, with experience developing antibodies, small molecules and cellular therapies at Harpoon Therapeutics, Astellas and Genentech.

Juvena Therapeutics senior vice president of clinical development. Physician and drug development executive with experience at Lilly, Procter & Gamble Pharmaceuticals, CV Therapeutics, Versartis and Eiger BioPharmaceuticals.

Juvena Therapeutics vice president of finance and operations, overseeing finance, people, technology and business operations. Previously held finance leadership roles at Genentech/Roche, Autodesk and Bio-Rad.

Juvena Therapeutics senior director of discovery and platform, with stem cell biology, bioinformatics and protein therapeutic screening expertise.

Juvena Therapeutics senior director of translational biology and pharmacology, with metabolic, hepatic, renal and ocular research experience. Previously led tissue regeneration discovery programs at Surrozen.

Juvena Therapeutics senior director of bioanalytical science, with biochemistry, immunology and protein engineering expertise, including protein expression and purification systems.

Juvena Therapeutics senior director of program management, with experience coordinating biologic and small molecule programs across research, clinical development, manufacturing and regulatory functions.

Bison Ventures founding partner and Juvena Therapeutics director. An engineer and investor focused on AI in the physical world, robotics, computational drug discovery and climate technology. Previously invested at Cascade Asset Management and Braemar Energy Ventures; earned engineering and engineering management degrees at Dartmouth.

Juvena Therapeutics independent director, also listed as Steven P. James in its financing announcement. Previously served as chief executive at Pionyr Immunotherapeutics, Labrys Biologics and KAI Pharmaceuticals.

Juvena Therapeutics independent director and former Genentech executive vice president, as identified in the company's current governance directory.

Juvena Therapeutics co-founder, chief scientific officer and director, overseeing research strategy, preclinical science and intellectual property. Has proteomics and systems biology research experience at UT Austin and Harvard.

Juvena Therapeutics chief executive and director, appointed in August 2026. Biotechnology executive with experience developing and commercializing medicines for rare and orphan diseases.

Juvena Therapeutics co-founder, director and executive adviser; formerly the company's chief executive. Research background in aging and degenerative disease biology informs its regenerative therapeutics platform.

Juvena Therapeutics board observer and scientific advisory board chairman, with earlier research sciences leadership at Merck.

Juvena Therapeutics board observer representing Mubadala Capital, explicitly listed in the current governance directory.

Juvena Therapeutics board observer representing Manta Ray, explicitly listed in the current governance directory.

Juvena Therapeutics board observer representing Horizons Ventures, explicitly listed in the current governance directory and named in its 2022 Series A announcement.

Vengadeshprabhu Karuppa Gounder is listed by Juvena Therapeutics as Senior Scientist II - Pharmacology, supporting its scientific discovery and operations team.

Sharon Louie is listed by Juvena Therapeutics as Senior Scientist II - Pharmacology, supporting its scientific discovery and operations team.

Ritwik Datta is listed by Juvena Therapeutics as Senior Scientist I, supporting its scientific discovery and operations team.

Rohit Jadhav is listed by Juvena Therapeutics as Senior Scientist II, supporting its scientific discovery and operations team.

Mingyu Chung is listed by Juvena Therapeutics as Senior Scientist I - Single Cell Genomics, supporting its scientific discovery and operations team.

Zhi Zheng is listed by Juvena Therapeutics as Scientist I, supporting its scientific discovery and operations team.

Danielle Yi is listed by Juvena Therapeutics as Scientist I, supporting its scientific discovery and operations team.

Trang Vuong is listed by Juvena Therapeutics as Scientist I, supporting its scientific discovery and operations team.

Munir Yousef is listed by Juvena Therapeutics as Senior Bioinformatics Analyst, supporting its scientific discovery and operations team.

Ashil Koranne is listed by Juvena Therapeutics as Associate Scientist, supporting its scientific discovery and operations team.

Megan Smith is listed by Juvena Therapeutics as Associate Scientist, supporting its scientific discovery and operations team.

Annie Yang is listed by Juvena Therapeutics as Senior Research Associate, supporting its scientific discovery and operations team.

Sarah Tang is listed by Juvena Therapeutics as Senior Research Associate, supporting its scientific discovery and operations team.

Jonathan Gaffney is listed by Juvena Therapeutics as Research Associate, supporting its scientific discovery and operations team.

Theodore Yu is listed by Juvena Therapeutics as Research Associate, supporting its scientific discovery and operations team.

Jamie Romero is listed by Juvena Therapeutics as Associate Director, Operations, supporting its scientific discovery and operations team.

Natalie Ploof is listed by Juvena Therapeutics as Lab Manager, supporting its scientific discovery and operations team.

Jefferson Life Sciences strategic adviser and biotechnology innovation executive. Previously led external innovation at Johnson & Johnson and has experience connecting startups, academic research and pharmaceutical partnerships.

Jefferson Life Sciences strategic adviser and Sanofi Ventures managing director, with earlier corporate development experience at Translate Bio and venture investment experience at Atlas Venture.

Jefferson Life Sciences strategic adviser and Mubadala Capital biotechnology investment partner. Previously held investment roles at RA Capital and Longitude Capital and helped build Epirium Bio.

Jefferson Life Sciences strategic adviser, Case Western Reserve University School of Medicine dean and regenerative medicine researcher with hematological oncology expertise.

Jefferson Life Sciences strategic adviser and medical technology executive with leadership experience at Cairdac, SamanTree Medical, Anaconda Biomed and SoniVie.

Jefferson Life Sciences strategic adviser and MIT professor specializing in biomedical engineering and cancer nanomedicine. A physician and engineer who directs MIT's Marble Center for Cancer Nanomedicine.

Jefferson Life Sciences investment analyst with a Yale doctorate in cellular and molecular physiology, researching visual neuroscience and ophthalmology. Previously a Canaan-Yale Fellow on Canaan Partners' healthcare investing team.

Jefferson Life Sciences senior associate with biotechnology investment and research experience at William Blair and Cleveland Clinic Ventures. Earned a life sciences doctorate at Northwestern University, studying reproductive organ-on-a-chip models.

Jefferson Life Sciences managing partner and biotechnology entrepreneur. Previously president and chief business officer at Satellite Bio and a founding team member at Valo Health, with company creation experience at Flagship Pioneering.

Camille Samuels is a healthcare venture investor named on Mission Bay Capital’s outside investment advisory committee. Its undated directory identifies her Venrock affiliation; Venrock’s2016 primary interview confirms she joined in2014 and discusses her work with life-science entrepreneurs and longevity science. These source-qualified advisory and historical affiliations are distinguished from Mission Bay employment or an inferred personal investment.

Biotechnology entrepreneur, also known as Ned David, who co-founded Syrrx, Achaogen, Kythera, UNITY and Jupiter Bioventures.

Physician and drug developer formerly serving as Merida Biosciences CMO and Cerevel Therapeutics development executive.

Mary Lynne Hedley joined Lilly’s board in 2022. She is a senior scientific fellow at the Broad Institute and a Third Rock Ventures venture partner. She co-founded TESARO in 2010 and served as president and chief operating officer before its 2019 acquisition by GSK.

Draig Therapeutics founder and head of biology, and Cardiff University Medicines Discovery Institute director. Specializes in GABA receptor biology, neuroscience drug discovery and human target engagement.

Draig Therapeutics chief medical officer and physician with neuroscience clinical development and regulatory experience. Previously held senior clinical development roles at Bristol Myers Squibb and Karuna Therapeutics.

Draig Therapeutics senior vice president of business operations and chief of staff. Previously a founding team member and strategic operations leader at Vigil Neuroscience, with experience at Ipsen, Teva and investment banks.

Draig Therapeutics senior vice president of program leadership and portfolio management. Neuropsychologist with clinical development experience at Convergence Pharmaceuticals and Eliem Therapeutics, where she served as chief development officer.

Draig Therapeutics senior vice president of people and culture. Has biotechnology and pharmaceutical talent leadership experience at Marengo, Allena, Theseus and Agenus, and a sociology doctorate from the Polish Academy of Sciences.

Draig Therapeutics senior director of finance. Previously held financial leadership roles at Summit Therapeutics and Gylden Pharma; a Fellow of the Association of Chartered Certified Accountants.

Draig Therapeutics director of corporate development and founding team member since 2024. Previously worked on biotechnology company creation at SV Health Investors and business development at Quell Therapeutics.

Draig Therapeutics president and chief executive. Previously founded and led Vigil Neuroscience through its IPO and acquisition by Sanofi in 2025; has business development experience at Ipsen, Teva and Dyax.

Douglas Williams serves as Chairman of the Board at CAMP4 Therapeutics. Biopharmaceutical executive and chairman of both CAMP4 and Draig Therapeutics. Previously held senior research leadership roles at Sana Biotechnology and Biogen and led Codiak BioSciences and ZymoGenetics.

Draig Therapeutics director representing ICG and former Draig chief medical officer, as identified in its launch announcement. Samantha Budd Haeberlein is an ALZpath director and neuroscience drug development executive. Her career includes neurodegeneration leadership at Biogen and earlier research and development roles at AstraZeneca.

Draig Therapeutics director and head of Access Biotechnology, with life sciences investment experience.

Draig Therapeutics director representing SR One, listed in the company's current public directory.

Draig Therapeutics director representing Canaan Partners, listed in the company's current public directory.

Draig Therapeutics director, whose current company directory identifies an outside affiliation with Q32 Bio.

Draig Therapeutics board observer representing Sanofi Ventures, listed in its current public directory.

Draig Therapeutics board observer representing ICG, listed in its current public directory.

Has been an Alto director since February 2024. His current Alto biography identifies him as co-chair of the UK Mental Health Mission and a University of Oxford professor, with prior neuroscience leadership at Johnson & Johnson and Janssen. He also serves on Draig Therapeutics’ scientific advisory board.

Draig Therapeutics scientific advisory board member, identified as head of early R&D at ViiV Healthcare in its current directory.

Draig Therapeutics scientific advisory board member, identified as an adjunct psychiatry professor at Yale University in its current directory.

Draig Therapeutics scientific advisory board member and University of Toronto professor of psychiatry and pharmacology, as identified in its current directory.

Schrödinger executive vice president and chief scientific officer for its platform, leading computational scientists and chemists. Earned his chemistry doctorate at Columbia University with Richard Friesner.

Schrödinger president and head of therapeutics R&D and chief strategy officer for partnerships. Joined in 2018 and leads drug development, strategic ventures and business development.

Schrödinger senior vice president of software development, with scientific software and computational chemistry expertise. Joined in 2003 following research training at MIT and Columbia University.

Schrödinger executive vice president and chief information officer, with high performance computing and information technology experience. Joined the company in 2009.

Schrödinger executive vice president and chief commercial officer, leading global software sales and marketing. Has extensive computational chemistry and software commercialization experience, including earlier Schrödinger sales leadership from 2017 to 2024.

Schrödinger senior vice president of software sales. Joined in 2014 and has led commercial activities in the Americas and Asia Pacific, following roles at ChemAxon and Accelrys.

Schrödinger senior vice president of discovery and preclinical development sciences. Joined in 2016 and has medicinal chemistry, discovery portfolio and preclinical development expertise.

Schrödinger senior vice president of materials science. Joined in 2012 and has computational materials modeling experience at Materials Design, Accelrys and Zyvex.

Schrödinger chief financial officer, joining in 2024 after serving as a managing director in Morgan Stanley's healthcare investment banking group. Previously worked as an electrical engineer at Boston Scientific.

Schrödinger senior vice president of biology and structural biology. Joined in 2017 and leads biological discovery and structural biology capabilities supporting drug development.

Schrödinger senior vice president of life science business. Joined in 2008 and has experience developing European life science software markets, partnerships and scientific customer relationships.

Schrödinger executive vice president, chief technology officer and chief operating officer for software. Joined in 2006 and has led development of scientific software including Maestro and LiveDesign.

Schrödinger chief corporate affairs officer and head of investor relations. Joined in 2020 after communications and investor relations roles at Gamida Cell and Sanofi.

Schrödinger senior vice president of life sciences products. Joined in 2002 and has computational chemistry and molecular docking expertise, including development of Glide.

Schrödinger chief legal officer and chief people officer. Joined in 2010 following intellectual property and commercial legal work at Oracle and DoubleClick.

Schrödinger senior vice president of scientific development. Joined in 2012 and specializes in physics-based drug discovery and free energy methods, with doctoral research at Columbia University.

Schrödinger president, chief executive and director. Joined the company in 2002, became CEO in 2017 and led its 2020 IPO; previously a chemistry professor at Rutgers University.

Schrödinger director and physician with clinical drug development experience, including service as Vertex Pharmaceuticals' chief medical officer and advisory work with Blackstone Life Sciences.

Schrödinger director and Motive Partners senior partner. Previously held senior executive roles during an eighteen-year career at IBM.

Schrödinger director with enterprise software sales and operating leadership experience. Previously led global sales at Red Hat and served as chief executive of Viridity Software.

Schrödinger director with biotechnology finance leadership experience. Previously served as chief financial officer at Nabriva Therapeutics and Synergy Pharmaceuticals.

Schrödinger director and drug discovery executive. Serves as Kallyope's R&D chair following service as its founding chief executive; previously spent three decades in research at Merck.

Schrödinger co-founder, director and scientific advisory chairman. Founded the company in 1990 and is a Columbia University chemistry professor specializing in computational chemistry and molecular modeling.

Schrödinger scientific adviser and Caltech professor with computational chemistry and materials simulation expertise, leading the Materials and Process Simulation Center.

Schrödinger scientific adviser and Columbia University researcher specializing in biophysics, structural bioinformatics and macromolecular electrostatics, including DelPhi and GRASP methods.

Schrödinger scientific adviser and UCSF pharmaceutical chemistry professor specializing in molecular docking, chemoinformatics and experimental drug discovery.

Schrödinger scientific adviser and University of Maryland researcher specializing in computational chemistry and machine learning, including therapeutic discovery at the Institute for Health Computing.

Professor of Neurology at UCL and a consultant neurologist at the National Hospital for Neurology and Neurosurgery; scientific founder and advisor of Focalis Bio. Distinct from the S2G Investments managing director of the same name.

Bernard Ravina is listed by Atlas Venture as atlas advisor. The same directory identifies an outside portfolio role: Founder and Chief Executive Officer, Vima Therapeutics. The affiliation belongs to Atlas’s biotechnology company-creation network. Company operating roles, advisory posts and prior appointments are distinguished from full-time fund-management employment; the profile does not establish a personal cash investment.

Founder of Nimbus, an electric vehicle startup in Ann Arbor that joined Y Combinator's Winter 2020 batch. YC currently lists Nimbus as inactive and identifies him as a former founder.

Nimbus Therapeutics chief financial officer with finance and biotechnology experience; previously CFO at Boston Pharmaceuticals and Catabasis Pharmaceuticals and a pharmaceuticals analyst at Cowen.

Nimbus Therapeutics president of research and development, overseeing discovery, nonclinical and clinical groups; joined as chief scientific officer in 2019 and has extensive drug discovery experience.

Nimbus Therapeutics senior vice president of chemistry with oncology medicinal chemistry experience; previously led Boston oncology chemistry at AstraZeneca and held drug discovery roles at Merck.

Nimbus Therapeutics senior vice president of clinical development and physician scientist with oncology clinical strategy and small molecule and immuno-oncology development experience.

Nimbus Therapeutics senior vice president of biology with precision oncology, cancer immunology and metabolic drug discovery experience; previously held research leadership roles at HotSpot Therapeutics, FogPharma and Agios.

Nimbus Therapeutics vice president of molecular sciences, with biochemistry, biophysics and structural biology expertise; previously worked at Delphia Therapeutics, MOMA Therapeutics and Novartis.

Nimbus Therapeutics vice president of program management and R&D strategic operations; previously led therapeutic programs at the Gates Medical Research Institute and Mersana Therapeutics.

Nimbus Therapeutics vice president of corporate affairs and communications with biotechnology communications, medical affairs and strategic operations experience at Shape Therapeutics, Wave Life Sciences, Sanofi and Biogen.

Nimbus Therapeutics vice president of medicinal chemistry, with experience in kinase, GPCR and lipase drug discovery; joined Nimbus in 2017 after a long career at Pfizer and Wyeth.

Nimbus Therapeutics vice president of chemistry, manufacturing and controls; previously led CMC at Achillion Pharmaceuticals, developing clinical candidates and their manufacturing processes.

Nimbus Therapeutics vice president of computational chemistry and structural biology; previously a computational chemistry director at GSK with structure-based drug discovery, informatics and ADME modeling experience.

Nimbus Therapeutics vice president of intellectual property, also known as Josh Roth; pharmaceutical patent attorney and chemist with experience at Bristol Myers Squibb, Novartis and Pfizer.

Nimbus Therapeutics vice president of information technology with biotechnology digital infrastructure and cybersecurity experience; previously held technology leadership roles at Orchard Therapeutics and AMAG Pharmaceuticals.

Nimbus Therapeutics vice president of drug metabolism, pharmacokinetics and clinical pharmacology, joining in 2024; previously led nonclinical disposition and bioanalysis at Bristol Myers Squibb and worked at Celgene, Amgen and Abbott.

Nimbus Therapeutics chief executive and director; previously chief business officer, with biotechnology financing, licensing and asset transaction experience at the company since 2014.

Nimbus Therapeutics chairman and co-founder, with biotechnology venture investment and company building experience at Atlas Venture.

Nimbus Therapeutics director with biopharmaceutical and medical device investment experience at Lightstone Ventures and Advanced Technology Ventures.

Nimbus Therapeutics director with pharmaceutical development and commercialization leadership experience at Inhibikase, Kala, Civitas, Blend and Sunovion.

Nimbus Therapeutics director and physician with clinical research, medical affairs and patient safety leadership experience; previously held research leadership roles at Agilent and Kaleido.

Nimbus Therapeutics director with healthcare finance and strategic advisory experience, including Havencrest Healthcare Partners and leadership of Grant Thornton's healthcare and life sciences practices.

Nimbus Therapeutics director and biotechnology investor with neuroscience research training; has investment experience at RA Capital Management spanning cell therapies, retinal disorders and neurodevelopmental diseases. Current source-verified RA affiliation: Laura Stoppel holds the source-published role of Partner within RA Capital Management’s Healthcare group. The individual directory reports joining in2016; a precise appointment day is not available. Published academic qualifications: PhD. Universities identified in the own biography: Harvard University, Massachusetts Institute of Technology. This affiliation supports the firm’s healthcare research, investment, company-building, planetary-health or operational work according to the stated group. Published adviser and venture-partner titles retain their scope and do not imply employment or a general-partner appointment. Specific personal checks are not inferred from affiliation.

Nimbus Therapeutics director and drug discovery executive with research and operating leadership experience at Navitor Pharmaceuticals and Sirtris.

Physician appointed Akili senior vice president and head of medical affairs November13,2018. Prior medical-affairs and clinical-development work included Pfizer psychiatry, Sanofi, PPD and Shire. This dated appointment does not establish current employment.

Managing director of Winning Mindset Ventures GmbH in Munich; identified in the company’s imprint as Dipl.-Betriebswirt Stephan Huber. Distinct from XISTA’s physician-scientist venture partner of the same name.

Tim Irish is published as UKI2S Advisory Board Member within the UK Innovation & Science Seed Fund ecosystem. His health-technology experience includes GSK, GE and Philips. He has taught at King’sCollegeLondon, served as NICE vice-chair and held external board appointments. This affiliation retains the published investment, operating or external-advisory scope; it does not establish a personal cash check or an appointment to every group subsidiary.

Pooja Sikka is a CBIV Venture Partner and practising medical doctor with more than 20 years in healthcare and life sciences. She was a Partner at Octopus Ventures and previously led EY UK’s healthcare corporate venture portfolio. She founded and exited a healthcare service business and has worked on digital health and healthcare adoption strategy. She holds an Imperial College MBA and medical qualifications.

SV Health Investors growth fund advisory board member and biopharmaceutical strategy adviser with experience in institutional investing and research and development valuation; co-founder of Mezzopointe.

SV Health Investors growth fund advisory board member with healthcare technology leadership experience at athenahealth, AMICAS and VitalWorks, and investment advisory experience at New Mountain Capital.

SV Health Investors growth fund advisory board member and healthcare executive with hospital network leadership experience at McLaren Health Care.

SV Health Investors growth fund advisory board member with pharmaceutical services executive and legal experience; previously led Leiters, Ricerca Biosciences and GeneraMedix.

SV Health Investors growth fund advisory board member and founder of Aerocare; formerly chief executive of AdaptHealth, with durable medical equipment and healthcare services experience.

SV Health Investors growth fund advisory board member and hospital system executive with healthcare operations and leadership experience at Methodist Le Bonheur Healthcare.

SV Health Investors growth fund advisory board member with healthcare services and technology operating experience, including Nordic Consulting Partners, Vitalize Consulting Solutions and Cross Country.

SV Health Investors growth fund advisory board member and healthcare entrepreneur; founder of Hightop Health and Maestro Health, with previous executive experience at Wondr Health and PayFlex.

SV Health Investors business support and office coordinator in London, joining in 2026; previously worked in executive support, audit and business management at HSBC and Société Générale.

SV Health Investors executive assistant supporting its biotechnology team, joining in 2025; previously supported executives at Glia Technologies, Ethos Capital and Three Bays Capital.

SV Health Investors finance director with fund finance and accounting experience at Evans Capital and several private investment firms; previously SV's controller.

SV Health Investors healthcare growth executive assistant with executive support and operations experience at Odyssey Therapeutics and American Renal Associates.

SV Health Investors executive assistant supporting its biotechnology team, joining in 2024; previously held executive support and human resources roles at Crosspoint Capital Partners and RA Capital Management.

SV Health Investors executive assistant supporting Kate Bingham and the London biotechnology team; previously worked at Credit Suisse.

SV Health Investors partner, chief financial officer and chief compliance officer; previously controller at CMGI @Ventures and a senior associate at PricewaterhouseCoopers.

SV Health Investors controller with finance and accounting experience at Bain Capital and PricewaterhouseCoopers.

SV Health Investors financial controller in London, joining in 2025; previously handled corporate and fund accounting at OpCapita.

SV Health Investors venture partner and drug discovery executive with immunometabolism company building experience at Sitryx; formerly led discovery research at UCB and Celltech.

SV Health Investors venture partner and physician scientist with biopharmaceutical research and clinical development leadership experience at Sitryx, Sobi, Aeglea, GSK and Roche Genentech. Ravi Rao is listed by Samsara BioCapital as Venture Partner. He joined Samsara’s venture-partner network in2022. His physician-scientist background spans development, manufacturing and commercialization; this role is preserved alongside independently documented SVHealth affiliation.

SV Health Investors executive in residence focused on healthcare financial risk and services; healthcare company founder with operating experience at Health Payment Systems, Minuteman Health, Averde and UnitedHealth Group.

SV Health Investors venture partner and biotechnology company builder with leadership experience at Enara Bio, Immunocore, Quartet Medicine and Annovation Biopharma.

SV Health Investors venture partner and antibody discovery scientist with biotechnology leadership experience at Alchemab and MedImmune; former chair of the UK BioIndustry Association.

SV Health Investors venture partner and pharmaceutical research leader with experience at Sitryx, Quench Bio and Pfizer, spanning inflammation, immunology and early clinical development.

SV Health Investors operating partner and drug discovery specialist; previously chief scientific officer of OMass Therapeutics and chief technology officer of Sosei-Heptares.

SV Health Investors venture partner and biotechnology executive with company building and business development experience at Mestag Therapeutics, Gyroscope Therapeutics, Orbit Biomedical and Freeline.

Listed as a venture partner on SV Health Investors' current roster; physician and drug development executive with previous chief medical officer roles at Circassia, Theravance Biopharma and ReViral.

SV Health Investors venture partner and physician scientist with transplantation and immunology experience; joined SV in 2025 after pharmaceutical leadership roles at GSK, Celgene and Janssen.

SV Health Investors executive in residence focused on healthcare provider models, services and technologies supporting value-based care; has payer and provider operating experience including CIGNA and UnitedHealth Group.

SV Health Investors operating partner and biotechnology company executive; founder and former chief executive of Rempex Pharmaceuticals and former chief executive of Mpex Pharmaceuticals.

SV Health Investors growth partner investing in healthcare services, medical device and pharmaceutical services, and healthcare information technology; previously a principal at Graham Partners.

SV Health Investors biotechnology senior associate, joining in 2026; previously a KB Investment investor and a drug discovery and biology leader at Roivant Sciences and Merck.

SV Health Investors operating partner and growth fund advisory board member; former chief executive of CAS Medical Systems and QDX, with medical device operating and transaction experience.

SV Health Investors managing partner focused on medical devices and healthcare services, with investment, fundraising and portfolio experience at the firm since 2002.

SV Health Investors managing partner leading medical device investments; formerly chief operating officer of Boston Scientific, with experience integrating acquisitions and developing medical technology businesses.

SV Health Investors healthcare growth senior associate, promoted in 2025; previously invested at Lineage Capital and advised life sciences companies at Putnam Associates.

SV Health Investors operating partner and growth fund advisory board member with medical device leadership experience at Resolution Medical, GI Supply, Hill-Rom and Medtronic.

SV Health Investors chairman, also known as Gene Hill, with healthcare services and information technology investment experience; formerly an Accel Partners partner and healthcare company executive.

SV Health Investors managing partner focused on healthcare services and growth companies; previously a partner at Ferrer Freeman & Co. and held investment roles at GE Capital and Prudential.

SV Health Investors' inaugural AI Fellow, joining its London office in July 2026 to implement AI workflows; previously worked on neurodegenerative drug development at Talisman Therapeutics and stem cell disease models at Pfizer's Neusentis.

SV Health Investors healthcare growth vice president, promoted in 2025 after joining in 2022; previously worked on healthcare and life sciences acquisitions at Thermo Fisher Scientific.

SV Health Investors biotechnology partner and life sciences company builder, joining in 2024 after 5AM Ventures; has operating experience across venture-backed therapeutic companies including Sage and Nido.

SV Health Investors managing partner investing in digital health, healthcare technology and growth-stage services; previously a general partner at Summit Partners and Edison Partners.

Antibody and biologics discovery specialist with experience developing therapeutic platforms and clinical-stage drugs at Cambridge Antibody Technology, MedImmune, AstraZeneca and Alchemab.

Academic hepatologist and Chair of Tissue Repair and Regeneration at the University of Edinburgh. He studies the cells and molecular pathways that cause organ fibrosis using single-cell and spatial genomics.

Neuroimmunology researcher and Professor of Pathology and Immunology at Washington University School of Medicine in St. Louis. His research on brain immune cells informs BioClec’s Alzheimer’s drug discovery program.

Head of IT at SV Health Investors, managing technology infrastructure in the UK and US and supporting biotechnology and dementia strategies.

London accountant at SV Health Investors supporting biotechnology and dementia strategies, with prior experience preparing management accounts at BE Offices.

UK chief compliance officer at SV Health Investors; previously led compliance at ACA Mirabella and worked at the Financial Conduct Authority.

Senior associate in investor relations at SV Health Investors, supporting biotechnology and dementia strategies; previously worked in academic communications and fundraising.

SV Health Investors operating partner supporting dementia and biotechnology strategies; neuroscientist, former Innovate UK chief executive and biotechnology company builder.

SV Health Investors venture partner associated with Dementia Discovery Fund; former Eli Lilly neurodegenerative disease chief scientific officer with tau and progranulin research experience. Mike Hutton is a TRIMTECH scientific adviser. He led neurodegeneration discovery at Eli Lilly from 2009 until retiring in October 2025, with later responsibilities covering genetic medicine. His earlier research at Mayo Clinic and MSD included genetic causes of frontotemporal dementia. This advisory role does not imply current Lilly employment.

Scientific adviser associated with Dementia Discovery Fund and neurologist researching neuroinflammation; directs the Luxembourg Centre for Systems Biomedicine.

SV Health Investors managing partner co-leading its biotechnology franchise, with investments in drug discovery and development; formerly chair of the UK Vaccine Taskforce.

Novoroo Bioscience project manager coordinating Australian research and collaborations; global health graduate and Tasmania doctoral researcher with prior Novoron laboratory experience.

Medicinal chemist contributing to Novoroo Bioscience; Monash University researcher with industry and academic experience in fragment-based drug discovery.

Novoroo Bioscience structural biologist with protein biochemistry and structural research experience at Cambridge, Sydney and Tasmania.

Novoroo Bioscience structural biologist using cryo-electron microscopy and biophysical methods to investigate LRP1 interactions; trained at Monash University and the University of Melbourne.

Novoroo Bioscience director and MStranslate co-founder; former laboratory researcher in multiple sclerosis at the University of Melbourne and science communication specialist.

Josh Makower is a senior adviser to Patient Square Capital, a Stanford professor and co-founder of Stanford Biodesign. His work combines medical-device entrepreneurship, investment and clinical innovation; he founded ExploraMed and previously worked with NEA.

Héloïse Percheron appears in Idinvest Partners’ August2020 primary directory as HR coordinator. The role belonged to the historical European investment manager’s published investment, investor-relations or corporate support platform, spanning venture/growth, private debt and dedicated portfolios. The named historical role is distinguished from the preserved later Eurazeo affiliations. Idinvest became Eurazeo Investment Manager and was subsequently absorbed into Eurazeo Global Investor. Joining and departure days and unpublished prior career or education details are not inferred.